Kat Attica General Hospital

The medical center is at the forefront of research in sepsis, particularly focusing on the Interferon-Gamma Endotype (IDS). This specific endotype is identified as a significant risk factor for increased mortality in sepsis patients, independent of infection type or comorbidities.

• Interferon-Gamma Blockade
• Monoclonal Antibody Therapies
• Endotype-Specific Treatment

The center's research aims to improve patient outcomes by utilizing emapalumab, a monoclonal antibody that targets and blocks IFNγ, potentially reducing mortality rates in this patient subset.

Specializing in the treatment of acute moderate to severe low back pain, the center is exploring the efficacy of combination therapies. The focus is on enhancing pain relief through innovative injectable solutions.

• Combination Therapy Efficacy
• Pain Management Techniques
• Patient-Reported Outcomes

By comparing the effectiveness of a combination of Thiocolchicoside and Diclofenac against Diclofenac alone, the center aims to establish superior pain management protocols for patients.